Lilly’s Foundayo shows cardiovascular safety in diabetes trial
Eli Lilly (NYSE:LLY) reported positive results from its Phase 3 ACHIEVE-4 trial for Foundayo, showing cardiovascular safety and efficacy in type 2 diabetes patients. The trial met its primary objective, with Foundayo demonstrating a 16% lower risk of MACE-4 compared to insulin glargine. Participants also showed significant A1C reduction and weight loss. The results were presented at the European Association for the Study of Diabetes meeting and published in The Lancet.
How this was made
The 30-second read
Why it matters
The data positions Foundayo as a competitive oral GLP‑1 therapy, potentially expanding Lilly's diabetes franchise and influencing market expectations for upcoming regulatory filings.
Market read
First‑time disclosure of pivotal Phase 3 data provides a fresh catalyst for LLY, likely prompting short‑term buying interest.
What to watch
Potential safety concerns from adverse events and regulatory review timelines.
Background
The ACHIEVE-4 trial compared Foundayo to insulin glargine in 2,749 participants across 16 countries, reporting hazard ratios for MACE‑4 and MACE‑3 and showing substantial A1C and weight reductions.
Ticker impact
Eli Lilly (LLY) released Phase 3 ACHIEVE-4 trial results showing non‑inferior cardiovascular safety and significant A1C and weight loss benefits for its oral GLP‑1 drug Foundayo.
upward pressure as investors price in the safety and efficacy results
Phase 3 data is a material catalyst for a late‑stage drug; market typically reacts positively to favorable cardiovascular outcomes.
Market effects
Strengthens outlook for GLP‑1 class and may boost peer biotech valuations.
US biotech sector could see modest gains.
Adds confidence to global diabetes‑treatment pipeline.
Counterpoint
If long‑term cardiovascular benefit remains uncertain, the rally could be limited.
Key entities
- companyEli Lilly and Company
Pharmaceutical company reporting the trial results.
- drugFoundayo (orforglipron)
Oral GLP‑1 receptor agonist under investigation.
